Pathophisiology of abdominal aortic aneurysm: biomarkers and novel therapeutic targets
Clin Investig Arterioscler. 2019 Jul-Aug;31(4):166-177.
doi: 10.1016/j.arteri.2018.10.002.
Epub 2018 Dec 7.
[Article in
English,
Spanish]
Authors
Monica Torres-Fonseca
1
, María Galan
2
, Diego Martinez-Lopez
1
, Laia Cañes
3
, Raquel Roldan-Montero
1
, Judit Alonso
4
, Teresa Reyero-Postigo
1
, Mar Orriols
4
, Nerea Mendez-Barbero
1
, Marc Sirvent
5
, Luis Miguel Blanco-Colio
1
, José Martínez
3
, Jose Luis Martin-Ventura
6
, Cristina Rodríguez
7
; En representación del Grupo de trabajo de Biología Vascular de la Sociedad Española de Arteriosclerosis
Affiliations
- 1 Vascular Research Lab, Instituto de Investigación Sanitaria, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, España; CIBER de Enfermedades Cardiovasculares (CIBERCV), España.
- 2 CIBER de Enfermedades Cardiovasculares (CIBERCV), España; Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, España.
- 3 CIBER de Enfermedades Cardiovasculares (CIBERCV), España; Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), IIB-Sant Pau, Barcelona, España.
- 4 CIBER de Enfermedades Cardiovasculares (CIBERCV), España.
- 5 Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.
- 6 Vascular Research Lab, Instituto de Investigación Sanitaria, Hospital Universitario Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, España. Electronic address: jlmartin@fjd.es.
- 7 CIBER de Enfermedades Cardiovasculares (CIBERCV), España; Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, España. Electronic address: crodriguezs@santpau.cat.
Abstract
Abdominal aortic aneurysm (AAA) is a vascular pathology with a high rate of morbidity and mortality and a prevalence that, in men over 65 years, can reach around 8%. In this disease, usually asymptomatic, there is a progressive dilatation of the vascular wall that can lead to its rupture, a fatal phenomenon in more than 80% of cases. The treatment of patients with asymptomatic aneurysms is limited to periodic monitoring with imaging tests, control of cardiovascular risk factors and treatment with statins and antiplatelet therapy. There is no effective pharmacological treatment capable of limiting AAA progression or avoiding their rupture. At present, the aortic diameter is the only marker of risk of rupture and determines the need for surgical repair when it reaches values greater than 5.5cm. This review addresses the main aspects related to epidemiology, risk factors, diagnosis and clinical management of AAA, exposes the difficulties to have good biomarkers of this pathology and describes the strategies for the identification of new therapeutic targets and biomarkers in AAA.
Keywords:
Abdominal aortic aneurysm; Aneurisma de aorta abdominal; Biomarcador; Biomarker; Factores de riesgo; Manejo terapéutico; Risk factors; Therapeutic management.
Copyright © 2018 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Aged
-
Aortic Aneurysm, Abdominal / diagnosis
-
Aortic Aneurysm, Abdominal / physiopathology*
-
Aortic Aneurysm, Abdominal / therapy
-
Aortic Rupture / prevention & control
-
Biomarkers / metabolism*
-
Disease Progression
-
Female
-
Humans
-
Male
-
Molecular Targeted Therapy*
-
Prevalence
-
Risk Factors